Medical Condition News

RSS

Liver surgery improves survival in people with bowel cancer

Patients with bowel cancer that has spread to the liver and who are eligible for surgery, are around 40 per cent more likely to survive if they undergo an operation to remove the liver disease.

2 Jun 2010

Survey: 58% of Australians worry about brain health, age-related degenerative brain disease

The majority of Australians (58%) are worried about their brain health and the threat of age-related degenerative brain disease, according to a new survey. The national survey was commissioned by leading medical research institute Neuroscience Research Australia and polled 1000 Australians aged 18 to over 75.

2 Jun 2010

Allos Therapeutics' FOLOTYN data to be presented at 46th ASCO and 15th EHA Congress

Allos Therapeutics, Inc. today announced that data on FOLOTYN® (pralatrexate injection) will be presented at two upcoming medical conferences: the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO), which will be held June 4-8 in Chicago, Illinois, and at the 15th Congress of the European Hematology Association (EHA), which will be held June 10-13 in Barcelona, Spain.

2 Jun 2010

New study provides further evidence of link between indoor tanning and melanoma

A new study has provided further evidence of a link between indoor tanning and melanoma, the deadliest form of skin cancer. Scientists at the University of Minnesota's School of Public Health and Masonic Cancer Centre claim that their study, which is published in the journal Cancer Epidemiology, Biomarkers and Prevention, "definitively links" the use of sunbeds to melanoma.

2 Jun 2010

Latinos have highest rates of eye disease: New research

New research suggests Latinos have the highest rates of eye disease in the United States, and one Los Angeles area clinic, Eye Physicians of Long Beach, is supremely prepared to meet the community's eye care needs.

2 Jun 2010

McGill University granted 'Orphan Drug Designation' for pulmonary infection drug fenretinide

In addition to their suffering, rare disease patients often have to face the harsh reality that few pharmaceutical companies will ever be able to offer new treatments for their condition because the costs of new treatments will never be recovered from such a small market. But there are ways they can be helped. The U.S. Food and Drug Administration's "Orphan Drug Designation" offers a wide range of benefits that help organizations developing treatments for diseases and conditions affecting fewer than 200,000 patients in the United States.

2 Jun 2010

Cancer patients should find ways to be physically active during and after treatment: New national guidelines

Cancer patients who've been told to rest and avoid exercise can - and should - find ways to be physically active both during and after treatment, according to new national guidelines. Kathryn Schmitz, PhD, MPH, an associate professor of Epidemiology and Biostatistics and a member of the Abramson Cancer Center at the University of Pennsylvania School of Medicine, will present these guidelines at an educational session at the 2010 meeting of the American Society of Clinical Oncology, aimed at making cancer exercise rehabilitation programs as common as those offered to people who have had heart attacks or undergone cardiac surgery.

2 Jun 2010

Scientists discover key mechanism of cancer cells

Many tumor cells would not be viable due to aberrant chromosome distribution if they had not developed a special trick. Scientists from the German Cancer Research Center have investigated which genes are responsible for this survival strategy of cancer cells.

2 Jun 2010

Onyx Pharmaceuticals commences Phase 1 study of ONX 0912 oral proteasome inhibitor for cancer

Onyx Pharmaceuticals, Inc. today announced the initiation of a Phase 1 study of ONX 0912, an oral proteasome inhibitor, in patients with advanced refractory or recurrent solid tumors.

2 Jun 2010

Study sheds light on molecular mechanisms of genital and urinary tract abnormalities

Scientists have learned how a gene widely known for precisely positioning and sculpting various organs also controls the speed of cell division, a finding that could be useful for understanding the explosive growth of cancer cells or why increasing numbers of children are being born with genital and urinary tract malformations.

2 Jun 2010

FDA accepts Orexigen's Contrave NDA for treatment of obesity

Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's New Drug Application (NDA) for Contrave® (naltrexone SR/bupropion SR), its investigational drug for the treatment of obesity.

2 Jun 2010

Over-the-counter supplements can cause hypertension and kidney failure

Negative health effects linked to taking too much supplemental calcium are on the rise, according to a commentary appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN).

2 Jun 2010

New model reveals molecular basis of multiple hereditary exostoses

Children born with multiple hereditary exostoses (MHE) suffer from abnormal growths on their bones. These bony protrusions stunt their growth and can cause pain and disfigurement.

2 Jun 2010

Results from AMRI's on-going Phase I clinical study of ALB 109564(a) published online

AMRI announced today that on-going results from its Phase I clinical study on its novel tubulin inhibitor, ALB 109564(a), were published on the website of the American Society of Clinical Oncology (abstract.asco.org/alb). These results indicate that ALB 109564(a) is well tolerated at the doses tested and shows preliminary evidence of clinical activity in disease types not typically treated with approved vinca alkaloids.

2 Jun 2010

CoaguSense unveils first portable point-of-care PT/INR Monitoring System for patients on oral anticoagulants

CoaguSense™, Inc., a diagnostic device company that has been in stealth mode for the past two years, today unveiled the first portable point-of-care Prothrombin Time/International Normalized Ratio (PT/INR) analyzer to directly detect blood clotting time for patients stabilized on oral anti-coagulation medications such as Coumadin® or warfarin.

2 Jun 2010

Bowel cancer to cost $1 billion by 2011 – more emphasis on screening programs needed

Findings from a new study show that more and more Australians are being diagnosed with bowel cancer and costs of treatment may well touch $1 billion next year a sharp rise from the $235 million in 2001. The study says that there are more than 13,500 Australians diagnosed with bowel cancer each year.

1 Jun 2010

Protox announces presentations on PRX302 for BPH at 2010 AUA Annual Meeting

Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced that two oral podium presentations on the company's lead candidate, PRX302, will be made at the 2010 Annual Meeting of the American Urological Association (AUA). These presentations will include six month data from the Phase 2b clinical study of PRX302 called TRIUMPH, in patients with moderate to severe benign prostatic hyperplasia (BPH).

1 Jun 2010

Belgian FAMHP approves Oncolytics' Phase 3 combination trial of REOLYSIN in head and neck cancers

Oncolytics Biotech Inc. today announced that it has received approval from the Belgian Federal Agency for Medicines and Health Products (FAMHP) to conduct its Phase 3 trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers. This is the same trial that was agreed to by U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process and the U.K. Medicines and Healthcare products Regulatory Agency (MHRA).

1 Jun 2010

Enrollment and dosing in NeuroDerm's Phase I clinical trial of ND0611 completed

NeuroDerm, Ltd. announced today the successful enrollment and dosing in its Phase I clinical trial of ND0611. ND0611, a proprietary drug formula administered via a dermal patch, is designed to maintain continuous therapeutic levodopa concentrations for improving the treatment of Parkinson's disease.

1 Jun 2010

Europe spends just 5% of total cancer research funds on metastases

On average, about five percent of total cancer research funding is spent on investigating metastases (the spread of cancer cells around the body) in Europe, yet metastatic disease is the direct or indirect cause of 90 percent of all cancer deaths, according to an editorial in the European Journal of Cancer (EJC).

1 Jun 2010

Medical Condition News

Liver surgery improves survival in people with bowel cancer

Survey: 58% of Australians worry about brain health, age-related degenerative brain disease

Allos Therapeutics' FOLOTYN data to be presented at 46th ASCO and 15th EHA Congress

New study provides further evidence of link between indoor tanning and melanoma

Latinos have highest rates of eye disease: New research

McGill University granted 'Orphan Drug Designation' for pulmonary infection drug fenretinide

Cancer patients should find ways to be physically active during and after treatment: New national guidelines

Scientists discover key mechanism of cancer cells

Onyx Pharmaceuticals commences Phase 1 study of ONX 0912 oral proteasome inhibitor for cancer

Study sheds light on molecular mechanisms of genital and urinary tract abnormalities

FDA accepts Orexigen's Contrave NDA for treatment of obesity

Over-the-counter supplements can cause hypertension and kidney failure

New model reveals molecular basis of multiple hereditary exostoses

Results from AMRI's on-going Phase I clinical study of ALB 109564(a) published online

CoaguSense unveils first portable point-of-care PT/INR Monitoring System for patients on oral anticoagulants

Bowel cancer to cost $1 billion by 2011 – more emphasis on screening programs needed

Protox announces presentations on PRX302 for BPH at 2010 AUA Annual Meeting

Belgian FAMHP approves Oncolytics' Phase 3 combination trial of REOLYSIN in head and neck cancers

Enrollment and dosing in NeuroDerm's Phase I clinical trial of ND0611 completed

Europe spends just 5% of total cancer research funds on metastases

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News